These findings suggest that clinicians and treatment guidelines should expand beyond monitoring only ALP and TB when assessing risk or determining the need to initiate first- or second-line therapy, by incorporating additional biomarkers such as ALT, AST and albumin. This evidence concerns the gene ALB and tuberculosis.